Published in Immunology on December 01, 1991
CRP after 2004. Mol Immunol (2004) 1.91
Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology (2003) 1.33
Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med (1992) 0.93
Cardiomyopathy is linked to complement activation. Am J Pathol (2002) 0.77
Functional transformation of C-reactive protein by hydrogen peroxide. J Biol Chem (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
N-hydroxysulfosuccinimide active esters: bis(N-hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry (1982) 2.63
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol (1974) 1.68
Interactions of C-reactive protein with the complement system. III. Complement-dependent passive hemolysis initiated by CRP. J Exp Med (1975) 1.48
Interactions of C-reactive protein with the first component of human complement. J Immunol (1977) 1.45
Inhibition of the reconstitution of the haemolytic activity of the first component of human complement by a pepsin-derived fragment of subcomponent C1q. Biochem J (1977) 1.40
Genomic DNA sequence for human C-reactive protein. J Biol Chem (1985) 1.39
Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol (1987) 1.27
Interaction of human Clq with insoluble immunoglobulin aggregates. Immunochemistry (1978) 1.13
Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes. Mol Immunol (1979) 1.11
Binding of human C-reactive protein to mouse macrophages is mediated by distinct receptors. J Immunol (1989) 1.08
Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol (1991) 1.08
Complement activation induced by human C-reactive protein in mildly acidic conditions. J Immunol (1990) 1.03
Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J Immunol (1989) 1.02
Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation (1988) 1.02
Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement. Biochem J (1980) 1.02
Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors. Immunology (1989) 0.95
Comparison of the enzymatic sensitivities of the platelet receptor for human C-reactive protein and its functional relationship to the platelet IgG Fc receptor. Clin Exp Immunol (1982) 0.89
Antigen-independent activation of the first component of complement C1 by chemically crosslinked rabbit IgG-oligomers. FEBS Lett (1980) 0.89
Neutrophil lysosomal degradation of human CRP: CRP-derived peptides modulate neutrophil function. Clin Exp Immunol (1988) 0.87
Enhancement of human peripheral blood monocyte respiratory burst activity by aggregated C-reactive protein. J Leukoc Biol (1986) 0.86
Complement fixation by model immune complexes free in solution and bound onto cell surfaces. Biochemistry (1979) 0.85
Macrophage tumoricidal activity induced by human C-reactive protein. Cancer Res (1986) 0.85
Preparation and characterization of chemically defined oligomers of rabbit immunoglobulin G molecules for the complement binding studies. Biochem J (1980) 0.83
Binding of human C-reactive protein (CRP) to plasma fibronectin occurs via the phosphorylcholine-binding site. Mol Immunol (1988) 0.81
Antigen-independent binding of IgG dimers to C 1 q as studied by sedimentation equilibrium, complement fixation and electron microscopy. Eur J Immunol (1980) 0.79
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med (1968) 3.33
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Interactions of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens. J Exp Med (1967) 2.87
Reaction of a cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes. Proc Soc Exp Biol Med (1969) 2.76
Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia. Int Arch Allergy Appl Immunol (1967) 2.64
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
The complement profile in acute glomerulonephritis systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol (1968) 2.38
C-reactive protein and the acute phase response. Adv Intern Med (1982) 2.20
Significance of complement to the mechanism of action of endotoxin. Curr Top Microbiol Immunol (1969) 2.18
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol (1976) 2.02
Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J Pediatr (1976) 1.98
Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med (1976) 1.95
Chronic glomerulonephritis associated with low serum complement activity (chronic hypocomplementemic glomerulonephritis). Medicine (Baltimore) (1970) 1.94
Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement. Proc Natl Acad Sci U S A (1969) 1.92
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Interactions of the complement system with native and chemically modified endotoxins. J Bacteriol (1968) 1.87
Decreased properdin activity in acute glomerulonephritis. Int Arch Allergy Appl Immunol (1969) 1.83
Regulation of complement activation by C-reactive protein. Immunopharmacology (1999) 1.78
C-reactive protein and the acute-phase response. J Lab Clin Med (1981) 1.67
Complement and complement-like activity in lower vertebrates and invertebrates. J Exp Med (1970) 1.61
Hormonal control of lysosomal enzyme release from human neutrophils. Effects of autonomic agents on enzyme release, phagocytosis, and cylic nucleotide levels. J Exp Med (1974) 1.58
Complement-dependent biological functions in complement deficiency in man. Lancet (1966) 1.56
Complement inactivation by serum from patients with acute and hypocomplementemic chronic glomerulonephritis. J Lab Clin Med (1968) 1.54
Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay. Immunology (1974) 1.49
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol (1990) 1.46
Interactions of C-reactive protein with the first component of human complement. J Immunol (1977) 1.45
Decreased C'-1q protein concentration and agglutinating activity in agammaglobulinaemia syndromes: an inborn error reflected in the complement system. Clin Exp Immunol (1968) 1.41
Structure and function of the pentraxins. Curr Opin Immunol (1995) 1.41
Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol (1976) 1.39
Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol (1975) 1.37
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37
Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg (1969) 1.37
Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet (1969) 1.36
Deficiency of C1r in human serum. Effects on the structure and function of macromolecular C1. J Exp Med (1970) 1.36
The role of C9 in complement-mediated killing of Neisseria. J Immunol (1981) 1.35
C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol (1974) 1.35
Complement in endotoxin shock: effect of complement depletion on the early hypotensive phase. Infect Immun (1970) 1.34
Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol (2000) 1.30
Deficiency of C7 with systemic lupus erythematosus: solubilization of immune complexes in complement-deficient sera. Arthritis Rheum (1981) 1.30
Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol (1987) 1.27
Interactions of the complement system with endotoxins from a Salmonella minnesota mutant deficient in O-polysaccharide and heptose. J Immunol (1968) 1.27
Complement and complement component activities in diseases associated with repeated infections and malignancy. Int Arch Allergy Appl Immunol (1968) 1.27
Activation and inhibition of IgG mediated complement fixation by staphylococcal protein A. Clin Exp Immunol (1970) 1.27
Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness. Immunology (1977) 1.27
Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action. Immunology (1975) 1.26
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation (1967) 1.25
The complement system in chronic glomerulonephritis: three newly associated aberrations. J Pediatr (1971) 1.21
Ontogenetic development of the complement system. Immunology (1969) 1.19
Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). J Exp Med (1988) 1.16
Chemiluminescence spectra of human myeloperoxidase and polymorphonuclear leukocytes. Infect Immun (1977) 1.14
Inhibition of platelet aggregation by native and desialised alpha-1 acid glycoprotein. Nature (1979) 1.13
Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations. J Immunol (1975) 1.13
Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J Immunol (1993) 1.13
Opsonic properties of C-reactive protein in vivo. J Immunol (1982) 1.13
Studies on the inhibition of C56-initiated lysis (reactive lysis). II. C567-INH--an inhibitor of the C567 trimolecular complex of complement. Int Arch Allergy Appl Immunol (1974) 1.12
Interactions of the complement system with endotoxic lipopolysaccharides in immunoglobulin-deficient sera. J Exp Med (1970) 1.11
Effects of hydrocortisone succinate on the complement system. Nature (1965) 1.11
Binding reactivity of C-reactive protein for polycations. J Immunol (1980) 1.10
C-reactive protein reactivity with complement and effects on phagocytosis. Ann N Y Acad Sci (1982) 1.10
A hypocomplementemic vasculitic urticarial syndrome. Report of four new cases and definition of the disease. Am J Med (1980) 1.08
Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol (1979) 1.08
C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol (1983) 1.08
Binding of C-reactive protein to human lymphocytes. II. Interaction with a subset of cells bearing the Fc receptor. J Immunol (1981) 1.08
Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol (1991) 1.08
Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry (1989) 1.07
A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27 Streptococcus pneumoniae. J Immunol (1982) 1.07
Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J Immunol (1981) 1.06
Binding of C-reactive protein to antigen-induced but not mitogen-induced T lymphoblasts. Science (1976) 1.06
C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol (1984) 1.06
Complement activation by interaction of polyanions and polycations. III. Complement activation by interaction of multiple polyanious and polycations is the presence of C-reactive protein. J Immunol (1977) 1.06
Interactions of the complement system with endotoxic lipopolysaccharide: the generation of an anaphylatoxin. Immunology (1969) 1.06
Restriction of complement-mediated membrane damage by the eighth component of complement: a dual role for C8 in the complement attack sequence. J Immunol (1979) 1.06
Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol (1983) 1.05
Binding of C-reactive protein to human lymphocytes. I. Requirement for a binding specificity. J Immunol (1981) 1.05
Complement activation by interaction of polyanions and polycations. Immunology (1976) 1.05
Effects of fraction I from Yersinia pestis on phagocytosis in vitro. J Infect Dis (1972) 1.04
Possible role for C-reactive protein in the human natural killer cell response. J Exp Med (1983) 1.03
Binding reactivity of C-reactive protein for polycations. II. Modulatory effects of calcium and phosphocholine. J Immunol (1981) 1.03
Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J Immunol (1989) 1.02
Activation of complement on the surface of cells infected by human immunodeficiency virus. J Immunol (1990) 1.02
Binding of human C-reactive protein to bacteria. Infect Immun (1982) 1.02
Effects of C-reactive protein on platelet function. III. The role of cAMP, contractile elements, and prostaglandin metabolism in CRP-induced inhibition of platelet aggregation and secretion. J Immunol (1977) 1.02
Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation (1988) 1.02
The role of the spleen in the protective effect of C-reactive protein in Streptococcus pneumoniae infection. Clin Exp Immunol (1983) 1.02
The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (1988) 1.02
Complement sensitivity of neuraminidase-treated lymphoid cells. Transplantation (1971) 1.01
Biology of C-reactive protein and the acute phase response. Hosp Pract (Hosp Ed) (1982) 1.00